Exelixis (EXEL) Other Accumulated Expenses (2010 - 2026)
Exelixis (EXEL) recorded quarterly Other Accumulated Expenses of $100.3 million in Q2 2026, down 20.02% quarter-over-quarter from $125.4 million in Q1 2026, and down 20.12% on a YoY basis from $125.6 million in Q2 2025.
Exelixis (EXEL) Other Accumulated Expenses (2010 - 2026) Analysis & Trends
Exelixis' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $100.3 million for Q2 2026.
- In Q2 2026, Other Accumulated Expenses fell 20.12% year-over-year to $100.3 million; the TTM figure through Apr 2026 stood at $100.3 million (down 20.12% YoY), while the FY2026 annual figure was $125.4 million, up 31.96% from the prior year.
- Other Accumulated Expenses was $100.3 million for Q2 2026 at Exelixis, down from $125.4 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $125.6 million in Q2 2025 to a low of $63.7 million in Q2 2022.
- Historically, Other Accumulated Expenses has averaged $99.0 million across 5 years, with a median of $101.4 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses jumped 55.39% in 2023, then declined 23.1% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $78.9 million in 2022, then surged by 37.37% to $108.4 million in 2023, then slipped by 11.71% to $95.7 million in 2024, then climbed by 9.3% to $104.6 million in 2025, then decreased by 4.14% to $100.3 million in 2026.
- The last three Other Accumulated Expenses figures came in at $100.3 million (Q2 2026), $125.4 million (Q1 2026), and $104.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 100.29 Mn |
| Jan 2, 2026 | 125.38 Mn |
| Oct 3, 2025 | 104.62 Mn |
| Jul 4, 2025 | 101.37 Mn |
| Apr 4, 2025 | 125.55 Mn |
| Jan 3, 2025 | 95.01 Mn |
| Sep 27, 2024 | 95.72 Mn |
| Jun 28, 2024 | 103.24 Mn |
| Mar 29, 2024 | 104.29 Mn |
| Dec 29, 2023 | 108.42 Mn |
| Sep 29, 2023 | 124.48 Mn |
| Jun 30, 2023 | 110.70 Mn |
| Mar 31, 2023 | 89.49 Mn |
| Dec 30, 2022 | 78.92 Mn |
| Sep 30, 2022 | 80.11 Mn |
| Jul 1, 2022 | 72.57 Mn |
| Apr 1, 2022 | 63.65 Mn |
| Dec 31, 2021 | 53.37 Mn |
| Oct 1, 2021 | 54.75 Mn |
| Jul 2, 2021 | 63.85 Mn |